Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2018-10-26 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
2018年第三季度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (337 characters) stating that the company's 2018 third quarter report has been disclosed on the official exchange website. It does not contain the actual financial data or substantive analysis but merely informs investors to refer to the full report elsewhere. According to the 'MENU VS MEAL' rule, this is a report publication announcement rather than the report itself.
2018-10-26 Chinese
2018年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled '量子高科（中国）生物股份有限公司 2018 年第三季度报告全文', which translates to 'Quantum Hi-Tech (China) Biological Co., Ltd. 2018 Third Quarter Report Full Text'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and segment analysis for the third quarter of 2018. The document includes comprehensive financial metrics, explanations of significant changes, and operational details for the quarter, indicating it is a substantive financial report for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR).
2018-10-26 Chinese
关于召开2018年第四次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2018 fourth extraordinary general meeting of shareholders for Quantum Hi-Tech (China) Biological Co., Ltd. It includes information about the meeting date, agenda items, voting procedures (including online voting), registration details, and attachments such as proxy forms and shareholder registration forms. There is no financial data or report content; rather, it is an announcement and procedural notice for a shareholder meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings.
2018-10-22 Chinese
非公开发行A股股票预案披露提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (682 characters) regarding a non-public issuance of A shares by Quantum Hi-Tech (China) Biological Co., Ltd. It mentions a pre-disclosure of the issuance plan and states that the proposal has been approved by the board but not yet submitted to the shareholders' meeting. The document does not contain financial statements or detailed financial data but is an update on capital raising plans. It is not a full capital/financing report but an announcement related to capital structure changes. Given the short length and nature of the content, it fits best under Capital/Financing Update (CAP).
2018-10-22 Chinese
2018年度创业板非公开发行股票预案
Capital/Financing Update Classification · 95% confidence The document is titled '2018 年度创业板非公开发行股票预案' which translates to '2018 Annual Non-public Issuance of Shares Proposal'. It is a detailed plan regarding a non-public stock issuance by Quantum Hi-Tech (China) Biological Co., Ltd. The content includes company background, issuance objectives, issuance targets, pricing, fundraising use, board approvals, regulatory compliance, and risk disclosures. It is a comprehensive proposal document related to capital raising through a non-public share issuance. There is no indication that this is an announcement of a report publication or a brief summary. The document is not an annual report, earnings release, or management discussion. It is clearly a capital/financing update detailing a fundraising activity and capital structure change. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2018-10-22 Chinese
第四届监事会第三次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the third meeting of the fourth Supervisory Board of Quantum Hi-Tech (China) Biological Co., Ltd. It includes multiple agenda items related to the company's non-public issuance of A shares, including the issuance plan, pricing, quantity, use of proceeds, and related party transactions. The document contains voting results for each resolution and references compliance with Chinese securities laws and regulations. The content focuses on decisions and approvals related to capital raising and financing activities, specifically a non-public stock issuance. There are no financial statements or quarterly/yearly financial performance data, so it is not an Annual Report or Interim Report. It is not a simple announcement of a report publication but a substantive disclosure of financing plans and approvals. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2018-10-22 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.